FUS

FUS Molekülinformation

Englischer Name	RNA-binding protein FUS	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	2	Target-Alias	75 kDa DNA-pairing protein，Fused in Sarcoma protein，Translocated in liposarcoma protein，POMp75，Oncogene TLS，Oncogene FUS
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Englischer Name	RNA-binding protein FUS
Target-Alias	75 kDa DNA-pairing protein，Fused in Sarcoma protein，Translocated in liposarcoma protein，POMp75，Oncogene TLS，Oncogene FUS
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	2
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

FUS Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag & MBP Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
FUS-H5144	Human	E. coli	Human FUS Protein, MBP,His Tag				In den Warenkorb legen

Gesamtmenge1

FUS Molekülhintergrund

FUS (RNA-binding protein FUS) is a DNA/RNA-binding protein that plays a role in various cellular processes such as transcription regulation, RNA splicing, RNA transport, DNA repair and damage response. It binds to nascent pre-mRNAs and acts as a molecular mediator between RNA polymerase II and U1 small nuclear ribonucleoprotein thereby coupling transcription and splicing. It binds also its own pre-mRNA and autoregulates its expression; this autoregulation mechanism is mediated by non-sense-mediated decay. FUS plays a role in DNA repair mechanisms by promoting D-loop formation and homologous recombination during DNA double-strand break repair. In neuronal cells, FUS plays crucial roles in dendritic spine formation and stability, RNA transport, mRNA stability and synaptic homeostasis.

FUS Molekülalias

75 kDa DNA-pairing protein,ALS6,amyotrophic lateral sclerosis 6,FUS1,fused in sarcoma,fus-like protein,Oncogene FUS,Oncogene TLS,RNA-binding protein FUS,POMP75,Translocated in liposarcoma,Translocated in liposarcoma protein

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Ulefnersen	ION-363	Phase 3 Clinical	Ionis Pharmaceuticals Inc	Amyotrophic Lateral Sclerosis	Details
RAG-21	RAG-21	Phase 1 Clinical	Ractigen Therapeutics (Nantong) Co Ltd	Amyotrophic Lateral Sclerosis	Details